Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
On the opposite side sPLA X has
2019-08-23

On the opposite side, sPLA2-X has also been implicated in the pathology of cancer [167,168]. Human sPLA2-X induces lipid droplet formation in Ras-driven MDA-MB-231 triple-negative breast cancer BRL 37344, sodium salt and promotes their survival during nutrient stress. It acts through the products o
-
The AURA trial was a phase I
2019-08-23

The AURA trial was a phase I/II study evaluating the safety, tolerability and activity of Osimertinib in patients with EGFR-mutated NSCLC progressing after a previous EGFR TKI. The phase I component of the study included a dose escalation part (Osimertinib 20mg to 240mg), using a rolling six design,
-
With respect to bone metabolism and ossification related gen
2019-08-23

With respect to ‘bone metabolism and ossification’-related genes, treatment of SaOS-2 osteoblast-like b 35 manufacturer with MS-10 up-regulated IGFBP-4, TG2, and SOST. Up-regulation of IGFBP-4 in SaOS-2 cells inhibits DNA and protein synthesis induced by IGF-1 (Kudo et al., 1995, Kudo et al., 1996)
-
Currently two approaches can be used individually or combine
2019-08-23

Currently, two approaches can be used individually or combinedly to overcome weak immunogenicity of subunit GNE-493 (Bookstaver et al., 2018; Moyle, 2017; Vartak and Sucheck, 2016). The first is to design particulate antigens. Virus-like particles (VLPs), for example—mainly derived from the capsid
-
Compounds were synthesized using a facile step convergent
2019-08-23

Compounds were synthesized using a facile 8-step convergent synthesis ( and ). Briefly, (Boc)cyclen (compound ) was coupled using TBTU to Fmoc- or Cbz-protected amino alkyl acids (–), followed by deprotection using 20% piperidine in DMF, or H on Pd/C, respectively (–) (). Deprotected linkers were c
-
Does a universal mechanism for TLS exist Our
2019-08-23

Does a universal mechanism for TLS exist? Our previous studies using the bacteriophage T4 DNA polymerase generated the model provided in Fig. 7 that quantifies the molecular forces influencing key steps in the polymerization pathway during the replication of a non-instructional versus miscoding DNA
-
br Materials and methods br Acknowledgments br
2019-08-23

Materials and methods Acknowledgments Introduction Proton pumps convert the energy of high-energy compounds into the histamine receptor antagonist of protons across biomembranes. They play two physiological roles: pH regulation and the formation of proton-motive forces in their membranes.
-
It is important to note that
2019-08-23

It is important to note that CRF1 may be activated during acute stress and early phases of anxiety disorders (Coric et al., 2010, Ising et al., 2007), as well the administration of Astressin 2B into the lateral septum did not have an effect on anxiety-like behavior in low-stress conditions but had a
-
Fostamatinib in TR provides requirements for qualification o
2019-08-23

TR-107330 (1996) provides requirements for qualification of commercial PLC. It uses the criteria of NUREG/CR-6421. EPRI TR-104159 (1995) includes experience about dedicating COTS SW for PLC-based digital systems such as DAFAS (Diverse Auxiliary Feedwater Actuation System) and Emergency Diesel Bus Lo
-
br Conclusion br Conflicts of interest br Acknowledgements
2019-08-23

Conclusion Conflicts of interest Acknowledgements This study was financially supported by The Science and Engineering Research Board (SERB), Department of Science & Technology (DST), Government of India under the Fast Track Scheme for Young Scientist to Dr. V. Dhananjayan (No: SB/FT/LS-140/
-
A similar pattern was observed for both tissues of
2019-08-23

A similar pattern was observed for both tissues of P. harpagos, evidencing the absolute predominance of acetylcholinesterase. As observed, no effects were attributed to Iso-OMPA. The hypothesis that the major cholinesterasic form is AChE was reinforced considering the higher hydrolytic activity, whi
-
In cholesterol synthesis HMG CoA reductase is the rate
2019-08-23

In cholesterol synthesis, HMG-CoA reductase is the rate limiting step in cholesterol biosynthesis. Statins or HMG-CoA reductase inhibitors are commonly used for management of hypercholesterolemia. The presence of an HMG-like moiety on these drugs allows them to competitively bind to the catalytic do
-
In summary we demonstrated the high potency
2019-08-23

In summary, we demonstrated the high potency of fluxametamide against M. domestica, L. striatellus, and T. urticae GABACls, which leads to high acaricidal/insecticidal effects on these arthropod pests. In contrast to its high potencies against the GABACls of arthropod pests, fluxametamide exhibited
-
BRD-K4477 manufacturer br Results and Discussion br Conclusi
2019-08-23

Results and Discussion Conclusion What we have shown here is that highly specific antagonist can be a very useful tool, can mimic gene KO experiments or even further dissect receptor function. We just took ETA antagonist as an example and found that ETA mediates physiological closure of DA wh
-
br Acknowledgements We thank Dr
2019-08-22

Acknowledgements We thank Dr. Tai-Yuan Yu and Miss Chun-Ping Chang for helping with the drug/DNA sequence specificity study. We also thank the Chemical Synthesis Core and the Pathology Core Laboratory of IBMS for synthesizing SL-1 and for performing the pathology analysis, respectively, and the T
16630 records 1019/1109 page Previous Next First page 上5页 10161017101810191020 下5页 Last page